Phaseline

Companies › MaaT Pharma

MaaT Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Other; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MaaT033
Pooled allogeneic fecal microbiotherapy
–Phase 2Transplant ComplicationFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05762211MaaT033Phase 2Transplant ComplicationOtherFeb 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Photozig Serum Life Science Europe Distribuidora Biolife SA de CV Circul'Egg Intervene Immune

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.